Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.
Conclusion: Treatment with sacubitril-valsartan provides reasonable value in reducing cardiovascular mortality and morbidity in patients with NYHA class II to IV heart failure.
Primary Funding Source: U.S. Department of Veterans Affairs and Institute for Clinical and Economic Review.
PMID: 27571284 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA Tags: Ann Intern Med Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Diovan | Enalapril | Heart | Heart Failure | Internal Medicine | Lisinopril | Medicaid | Medicare